What were the main drivers of Pfizer's revenue growth in Q1 2003?

Pfizer's revenue growth of 10% to $8.525 billion in the first quarter of 2003 was primarily driven by a 4.7% increase in volume, a 2.0% increase in price, and a 3.3% favorable impact from foreign exchange rates. Strong performance from in-line products and newly launched products across major businesses and regions contributed to this growth.

How did the acquisition of Pharmacia impact Pfizer's financial statements for this period?

The acquisition of Pharmacia Corporation was completed on April 16, 2003, which is after the period end date of March 30, 2003. Therefore, Pharmacia's assets, liabilities, and results of operations are not reflected in these condensed consolidated financial statements. Their financial impact will be recognized prospectively from April 16, 2003, in future filings.

What significant divestitures occurred during the quarter?

Pfizer divested several consumer product businesses that did not align with its strategic goals. Notably, the Adams confectionery products business was sold for $4.2 billion, and the Schick-Wilkinson Sword shaving products business was sold for $930 million. These sales resulted in substantial gains, significantly boosting the quarter's net income.

What is the outlook for Pfizer following the Pharmacia acquisition?

Pfizer expects the acquisition of Pharmacia to significantly extend its leadership position in the global pharmaceutical industry. The company plans to provide an update on the initiatives and anticipated outcomes, including financial projections, resulting from the combination at an analyst meeting scheduled for June 2003.

PFE 10-Q Quarterly Report Q1 FY2003 — Revenue, Net Income, EPS

Summary

Pfizer Inc. reported strong financial results for the first quarter ended March 30, 2003, with revenues increasing by 10% to $8.5 billion and net income more than doubling to $4.7 billion, largely driven by significant gains from the divestiture of consumer product businesses. The company highlighted robust performance in its Pharmaceutical segment, with key products like Lipitor and Norvasc showing substantial growth. A major event subsequent to the quarter was the completion of the acquisition of Pharmacia Corporation on April 16, 2003, a significant strategic move expected to enhance Pfizer's leadership position in the global pharmaceutical industry. Investors should note the strategic shift indicated by the sale of consumer businesses, focusing resources on the core pharmaceutical operations. The upcoming analyst meeting in June will provide further insights into the financial projections and anticipated outcomes of the combined Pfizer-Pharmacia entity.

Key Highlights

1Revenues for the first quarter of 2003 increased by 10% to $8.525 billion compared to $7.747 billion in the prior year period.
2Net income more than doubled, reaching $4.665 billion ($0.76 per diluted share) in Q1 2003, compared to $1.963 billion ($0.31 per diluted share) in Q1 2002. This substantial increase was significantly boosted by gains from the sale of discontinued operations.
3Significant gains were realized from the sale of consumer businesses: Adams confectionery products ($1.824 billion net of tax) and Schick-Wilkinson Sword shaving products ($262 million net of tax).
4The acquisition of Pharmacia Corporation was completed on April 16, 2003, for approximately $56 billion in a stock-for-stock transaction, positioning Pfizer for expanded leadership in the pharmaceutical industry.
5The Pharmaceutical segment saw revenues grow by 12% to $7.929 billion, driven by strong performance in human pharmaceuticals, including key products like Lipitor and Norvasc.
6The company continued its share repurchase program, with approximately $1.9 billion spent on repurchasing shares in the period from January 1, 2003, to April 30, 2003.
7Research and Development (R&D) expenses increased by 3% to $1.218 billion, reflecting continued investment in new product development.

PFIZER INC Quarterly Report for Q1 Ended Mar 30, 2003

Summary

Key Highlights

Frequently Asked Questions